Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Palvella Therapeutics Q3 2026 Results: Net Loss of $24.6M, Loss Widens

Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals) filed its Q3 2026 10-Q following its 2024 merger with Legacy Palvella. The company is focused on developing its lead product candidate, QTORIN rapamycin, for rare skin diseases and reported 14,618,457 shares of common stock outstanding as of November 2, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-24.6-11.3
Net income-24.6-11.3
EPS (diluted, $ a share)$-1.70$-1.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PVLA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Palvella Therapeutics, Inc.: key numbers

Share price
$144.60Close, Nov 16
Market cap
$2.11B
Shares outstanding
14.62MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Palvella Therapeutics, Inc.

All →
6:55 PM ET Form 4
Insider Selling

Palvella Therapeutics CSO Jeffrey S. Martini Sells $2.08M of Stock

Jeffrey S. Martini, CSO, sold 12,500 shares of Palvella Therapeutics, Inc. at $163.34 to $172.12 a share (average $166.65) in 13 transactions, worth $2.08M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 0 (-100.0%).

Value
$2.08M
Shares
12,500
Average price
$166.65
Role
CSO
Holding change
-100.0%
Trade date
Nov 10, 2026 to Nov 11, 2026
7:31 AM ET 8-K
Financial Results

Palvella Therapeutics Financial Results

Palvella Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance and Priority Review of its NDA for QTORIN™ rapamycin in microcystic lymphatic malformations. The company ended the quarter with $236.7 million in cash and is preparing for a potential U.S. commercial launch in the first half of 2027 following a February 28, 2027 PDUFA date.

Term
Q3 2026

“With the FDA’s acceptance of our NDA for QTORIN™ rapamycin in microcystic lymphatic malformations and granting of Priority Review, we believe we are closer than ever to bringing our first therapy to patients.”

Wes Kaupinen, Founder and Chief Executive Officer

“Our focus is clear: successfully obtain FDA approval and bring our first therapy to patients, advance multiple additional QTORIN™ programs to approval, and build the leading company addressing serious, rare skin diseases and vascular anomalies.”

Wes Kaupinen, Founder and Chief Executive Officer
7:30 AM ET 8-K
Business Update

Palvella Therapeutics Business Update

Palvella Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel and granted it Priority Review. The application seeks approval for the treatment of microcystic lymphatic malformations, with a PDUFA target action date set for February 28, 2027.

4:06 PM ET Form 4
Insider Selling

Palvella Therapeutics COO Kathleen Goin Sells $537K of Stock

Kathleen Goin, COO, sold 4,313 shares of Palvella Therapeutics, Inc. at $123.62 to $126.19 a share (average $124.58) in 3 transactions, worth $537K in total on Oct 21, 2026. Shares held after the trade: 0 (-100.0%).

Value
$537K
Shares
4,313
Average price
$124.58
Role
COO
Holding change
-100.0%
Trade date
Oct 21, 2026
7:14 PM ET Form 4
Insider Selling

Palvella Therapeutics Insider George M. Jenkins Sells $3.58M of Stock

George M. Jenkins sold 27,500 shares of Palvella Therapeutics, Inc. at $121.14 to $136.44 a share (average $130.16) in 17 transactions, worth $3.58M in total between Oct 12, 2026 and Oct 14, 2026. Shares held after the trade: 132,616 (-0.4%).

Value
$3.58M
Shares
27,500
Average price
$130.16
Holding change
-0.4%
Trade date
Oct 12, 2026 to Oct 14, 2026
4:05 PM ET Form 4
Insider Selling

Palvella Therapeutics COO Kathleen Goin Sells $655K of Stock

Kathleen Goin, COO, sold 4,302 shares of Palvella Therapeutics, Inc. at $151.16 to $153.24 a share (average $152.24) in 3 transactions, worth $655K in total on Sep 16, 2026. Shares held after the trade: 0 (-100.0%).

Value
$655K
Shares
4,302
Average price
$152.24
Role
COO
Holding change
-100.0%
Trade date
Sep 16, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.